Rxivist logo

Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine

By Florian Krammer, Komal Srivastava, PARIS team, Viviana Simon

Posted 01 Feb 2021
medRxiv DOI: 10.1101/2021.01.29.21250653

As COVID-19 vaccines are getting rolled out, an important question is arising: Should individuals who already had a SARS-CoV-2 infection receive one or two shots of the currently authorized mRNA vaccines. In this short report, we are providing evidence that the antibody response to the first vaccine dose in individuals with pre-existing immunity is equal to or even exceeds the titers found in naive individuals after the second dose. We also show that the reactogenicity is significantly higher in individuals who already have been infected with SARS-CoV-2 in the past. Changing the policy to give these individuals only one dose of vaccine would not negatively impact on their antibody titers, spare them from unnecessary pain and free up many urgently needed vaccine doses.

Download data

  • Downloaded 65,322 times
  • Download rankings, all-time:
    • Site-wide: 78
    • In allergy and immunology: 2
  • Year to date:
    • Site-wide: 2
  • Since beginning of last month:
    • Site-wide: 2

Altmetric data


Downloads over time

Distribution of downloads per paper, site-wide


PanLingua

Sign up for the Rxivist weekly newsletter! (Click here for more details.)


News